Malignant Primary Bone Tumours

Very rare when considered alongside other forms of primary malignancy (<1% of all new malignancies)

Aetiology

  • Majority are idiopathic
  • Can occur at any age but more common in young patients - 10% of childhood cancers

Risk factors

  • Previous radiotherapy
  • Predisposing conditions: Paget's, fibrous dysplasia, multiple enchondromas
  • Genetic causes: Li Fraumeni syndrome (p53), familial retinoblastoma (RBI)

Clinical presentation

Symptoms

  • Presentation is often late in the disease
  • Higher index of suspicion in younger patients (10-30 years)
  • Persistent, increasing pain
    • Usually not associated with movement
    • Well localised
    • Worse at night
    • Not uncommonly misdiagnosed for muscular pains - any unexplained persistent skeletal pain/red flags should be further investigated
  • Pathological fracture

Signs

  • Swelling and erythema over joint (especially in Ewing's sacroma)
  • Palpable mass

Types of malignancy

Multiple myeloma

  • Malignant disease of the plasma cells of the bone marrow
  • Commonest primary tumour of bone
Clinical presentation
  • Generally affects elderly patients
  • 4 main features are hypercalcaemia, anaemia, renal impairment and bone pain

Osteosarcoma

  • Malignant tumour which produces bone
  • Most common primary sarcoma of bone
  • Metastatic spread is usually haematogenous but can be lymphatic
Clinical presentation
  • Most cases seen in adolescence and early adulthood
  • 2nd peak in the elderly associated with Paget's
  • 60% involve the bones around the knee (distal femur/proximal tibia), other sites include proximal femur, proximal humerus and pelvis
  • 10-20% of patients have pulmonary metastases at diagnosis - impacts survival

Chondrosarcoma

  • Cartilage producing primary bone tumour - malignancy of chondrocytes
  • Less common and less aggressive than osteosarcoma (generally - can be aggressive)
  • Majority arise de novo, few arise from benign lesions (enchondroma, osteochondroma)
  • Prognosis dependent on histological grade - majority are low grade
  • Can be very large and are slow to metastasize
Clinical presentation
  • Tends to be found in the older age group - mean age 45
  • Tend to be found in the pelvis or proximal femur

Fibrosarcoma and malignant fibrous histiocytoma

  • Fibrous malignant primary bone tumours which tend to occur in abnormal bone e.g. bone infarct, post radiation
  • Fibrosarcoma tends to affect adolescents/YAs

Ewing's sarcoma

  • Primary bone tumour of the endothelial cells of the bone marrow
  • 2nd commonest malignant bone tumour in children
  • Characterised by loss of bone (lysis)
Clinical presentation
  • Affects young people 5-25 years of age, most common age 10-20
  • Hot, swollen, tender joint or limb with raised inflammatory markers - can mimic infection
  • Usually found in diaphysis of long bones - distal femur, proximal tibia

Investigations

  • X-ray - aggressive and destructive signs including cortical destruction, a periosteal reaction, new bone formation (sclerosis and lysis), reactive cortical thickening (chondrosarcoma) and extension into the surrounding soft tissue envelope
    • AP and lateral including joint above and below
    • Bony lesions may not show up on x-rays until more than 50% of the cortical bone is lost - if x-ray normal but clinical suspician is high perform further imaging
  • Biopsy required for histological diagnosis and grading before surgery
  • Staging - bone scan, CT, MRI

Management

  • Surgery - removal of tumour and surrounding tissue, with joint reconstruction
    • Typically margin of 3-4cm of bone and a cuff of normal muscle all around
    • Amputations were more commonly used in the past but with improved adjuvant therapy limb salvage surgery has equivalent sucess rate (if appropriate)
  • Adjuvant chemotherapy/radiotherapy used if appropriate
    • Chondrosarcomas are not radiosensitive and are unresponsive to adjuvant chemotherapy
    • Osteosarcomas are not radiosensitive but adjuvant chemotherapy can prolong survival
  • Neo-adjuvant chemotherapy can improve survival